{"product_id":"wc-0efe51bcb5f34c14-50442","title":"Heart Failure Society of America Annual Scientific Meeting 2026","description":"\u003cdiv\u003e\r\n\u003ch1 data-pm-slice=\"1 1 []\"\u003eHeart Failure Society of America Annual Scientific Meeting 2026\u003c\/h1\u003e\r\n\u003ch2\u003eHFSA Annual Scientific Meeting 2026 | Advanced Heart Failure, HFrEF, HFpEF, GDMT, Cardiogenic Shock, LVAD, Heart Transplantation, Cardiomyopathies, Cardiorenal-Metabolic Medicine \u0026amp; Late-Breaking Clinical Trials\u003c\/h2\u003e\r\nThe \u003cstrong\u003eHeart Failure Society of America Annual Scientific Meeting 2026\u003c\/strong\u003e is a multidisciplinary cardiovascular educational conference focused on the prevention, diagnosis, treatment, and long-term management of heart failure and related cardiac conditions.\r\n\r\nOrganized by the \u003cstrong\u003eHeart Failure Society of America (HFSA)\u003c\/strong\u003e, the 2026 Annual Scientific Meeting brought together leading heart failure specialists, cardiologists, cardiovascular surgeons, researchers, pharmacists, nurses, advanced practice providers, and allied healthcare professionals.\r\n\r\nHeld \u003cstrong\u003eOctober 9–12, 2026\u003c\/strong\u003e, at the \u003cstrong\u003ePhoenix Convention Center in Phoenix, Arizona\u003c\/strong\u003e, the meeting delivered scientific education spanning advanced heart failure, cardiac transplantation, cardiogenic shock, cardiac devices, cardiomyopathies, heart failure pharmacotherapy, and multidisciplinary cardiovascular care.\r\n\r\nThe \u003cstrong\u003eHFSA Annual Scientific Meeting 2026\u003c\/strong\u003e program explored contemporary developments in guideline-directed medical therapy (GDMT), heart failure with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), preserved ejection fraction (HFpEF), cardiac amyloidosis, hypertrophic cardiomyopathy, cardiorenal-metabolic disease, ventricular assist devices, and emerging diagnostic and therapeutic technologies.\r\n\r\nThe conference featured plenary presentations, late-breaking clinical research, expert debates, multidisciplinary sessions, scientific abstracts, case-based discussions, and practical educational activities.\r\n\r\nAdditional topics included artificial intelligence in heart failure care, remote patient monitoring, cardiovascular genetics, cardio-oncology, health equity, prevention, implementation science, and improving clinical outcomes through coordinated team-based care.\r\n\u003ch2\u003eCourse Details\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e Heart Failure Society of America Annual Scientific Meeting 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAbbreviation:\u003c\/strong\u003e HFSA ASM 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOrganizer:\u003c\/strong\u003e Heart Failure Society of America (HFSA)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eDates:\u003c\/strong\u003e October 9–12, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Phoenix, Arizona, USA\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Venue:\u003c\/strong\u003e Phoenix Convention Center\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Program Venue:\u003c\/strong\u003e Sheraton Phoenix Downtown\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Format:\u003c\/strong\u003e In-Person Scientific Meeting with On-Demand Access for Registered Attendees\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eDuration:\u003c\/strong\u003e Four Days\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Specialty:\u003c\/strong\u003e Cardiology \/ Heart Failure Medicine\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Focus:\u003c\/strong\u003e Advanced Heart Failure, Transplant Cardiology, Cardiomyopathies, Cardiac Electrophysiology, Critical Care and Cardiovascular Research\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003e2026 Program Committee Chair:\u003c\/strong\u003e Jennifer Thibodeau, MD, MSCS, FHFSA, FACC, FAHA\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Methods:\u003c\/strong\u003e Plenary Sessions, Clinical Research, Scientific Abstracts, Debates, Workshops and Case Discussions\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Attendee On-Demand Access:\u003c\/strong\u003e Through January 7, 2027\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eMedicalAmboss Digital File Inventory:\u003c\/strong\u003e Not Independently Verified\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe original HFSA scientific meeting and any separately distributed educational materials should be treated as distinct offerings.\r\n\u003ch2\u003eTarget Audience\u003c\/h2\u003e\r\nThe conference is designed for healthcare professionals involved in the care of patients with heart failure and cardiomyopathy.\r\n\r\nThe target audience includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHeart Failure Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Heart Failure Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eTransplant Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eGeneral Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eInterventional Cardiologists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Electrophysiologists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiothoracic Surgeons\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Transplant Surgeons\u003c\/li\u003e\r\n \t\u003cli\u003eCritical Care Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eInternists\u003c\/li\u003e\r\n \t\u003cli\u003eHospitalists\u003c\/li\u003e\r\n \t\u003cli\u003eNephrologists\u003c\/li\u003e\r\n \t\u003cli\u003eEndocrinologists\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonologists\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Geneticists\u003c\/li\u003e\r\n \t\u003cli\u003eCardio-Oncology Specialists\u003c\/li\u003e\r\n \t\u003cli\u003ePalliative Care Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Pharmacists\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Nurses\u003c\/li\u003e\r\n \t\u003cli\u003eCardiology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Heart Failure and Transplant Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Researchers\u003c\/li\u003e\r\n \t\u003cli\u003eAllied Healthcare Professionals\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe meeting is particularly relevant to clinicians seeking updates on advanced heart failure therapeutics, mechanical circulatory support, cardiac transplantation, inherited cardiomyopathies, and clinical trial evidence.\r\n\u003ch2\u003eProgram Overview\u003c\/h2\u003e\r\nHeart failure is a complex clinical syndrome associated with impaired cardiac function, cardiovascular and systemic comorbidities, recurrent hospitalizations, and substantial effects on patient quality of life.\r\n\r\nContemporary management requires an understanding of medical treatments, cardiac devices, mechanical support, clinical monitoring, disease-specific therapies, and multidisciplinary care.\r\n\r\nThe \u003cstrong\u003eHFSA Annual Scientific Meeting 2026\u003c\/strong\u003e addresses these challenges through a broad educational program.\r\n\r\nMajor scientific and clinical areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHeart Failure with Reduced Ejection Fraction\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure with Mildly Reduced Ejection Fraction\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure with Preserved Ejection Fraction\u003c\/li\u003e\r\n \t\u003cli\u003eGuideline-Directed Medical Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Decompensated Heart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eMechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eLeft Ventricular Assist Devices\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Amyloidosis\u003c\/li\u003e\r\n \t\u003cli\u003eHypertrophic Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Sarcoidosis\u003c\/li\u003e\r\n \t\u003cli\u003eMyocarditis\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic Cardiomyopathies\u003c\/li\u003e\r\n \t\u003cli\u003eCardiorenal Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Dysfunction\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eMineralocorticoid Receptor Antagonists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Resynchronization Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eImplantable Cardioverter-Defibrillators\u003c\/li\u003e\r\n \t\u003cli\u003eConduction System Pacing\u003c\/li\u003e\r\n \t\u003cli\u003eCatheter Ablation\u003c\/li\u003e\r\n \t\u003cli\u003eRemote Hemodynamic Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eArtificial Intelligence\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eHealth Equity\u003c\/li\u003e\r\n \t\u003cli\u003ePalliative Care\u003c\/li\u003e\r\n \t\u003cli\u003eLate-Breaking Clinical Research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe curriculum emphasizes connecting scientific advances with practical treatment decisions and patient-centered cardiovascular care.\r\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\r\nBased on the educational scope of the 2026 program, participants should be better able to:\r\n\u003col start=\"1\" data-spread=\"true\"\u003e\r\n \t\u003cli\u003eImplement contemporary guideline-directed medical therapy for patients with HFrEF, HFmrEF, and HFpEF.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate emerging pharmacological treatments and clinical trial findings relevant to heart failure management.\u003c\/li\u003e\r\n \t\u003cli\u003eAssess and manage acute decompensated heart failure and cardiogenic shock using appropriate clinical monitoring and treatment strategies.\u003c\/li\u003e\r\n \t\u003cli\u003eReview patient selection, perioperative considerations, and long-term management of mechanical circulatory support and heart transplantation.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize important clinical features of cardiac amyloidosis, hypertrophic cardiomyopathy, cardiac sarcoidosis, myocarditis, and inherited cardiomyopathies.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate the relationship between cardiac, renal, and metabolic disease in contemporary heart failure care.\u003c\/li\u003e\r\n \t\u003cli\u003eReview indications and clinical considerations for electrophysiological interventions and cardiac device therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eAssess developments involving remote monitoring, digital health, and artificial intelligence.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate multidisciplinary care, health equity, and appropriate palliative care into heart failure management.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret scientific research and apply relevant evidence to individualized clinical decision-making.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive HFSA 2026 Scientific Program\u003c\/h1\u003e\r\nThe following sections organize the confirmed major educational themes of the original meeting. They are not presented as a complete lecture-by-lecture recording inventory.\r\n\u003ch2\u003eSession I – Guideline-Directed Medical Therapy\u003c\/h2\u003e\r\n\u003ch3\u003eContemporary Management of HFrEF\u003c\/h3\u003e\r\nHeart failure with reduced ejection fraction requires comprehensive medical treatment, appropriate risk assessment, and longitudinal care.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHFrEF Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eGuideline-Directed Medical Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eARNI Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eACE Inhibitors and ARBs\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Beta-Blockers\u003c\/li\u003e\r\n \t\u003cli\u003eMineralocorticoid Receptor Antagonists\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eMedication Optimization\u003c\/li\u003e\r\n \t\u003cli\u003eBlood Pressure and Renal Function\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Tolerability\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHeart Failure with Mildly Reduced Ejection Fraction\u003c\/h3\u003e\r\nRelevant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHFmrEF Classification\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Phenotypes\u003c\/li\u003e\r\n \t\u003cli\u003eComorbidity Assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacological Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHeart Failure with Preserved Ejection Fraction\u003c\/h3\u003e\r\nHFpEF is a major focus of modern heart failure research.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHFpEF Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eEchocardiography\u003c\/li\u003e\r\n \t\u003cli\u003eDiastolic Function\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Intolerance\u003c\/li\u003e\r\n \t\u003cli\u003eVolume Management\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eObesity\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension\u003c\/li\u003e\r\n \t\u003cli\u003eAtrial Fibrillation\u003c\/li\u003e\r\n \t\u003cli\u003eComorbidity Management\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Treatments\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational emphasis is on treatment individualization and understanding the diversity of HFpEF clinical presentations.\r\n\u003ch2\u003eSession II – Acute Decompensated Heart Failure and Cardiogenic Shock\u003c\/h2\u003e\r\n\u003ch3\u003eAcute Decompensated Heart Failure\u003c\/h3\u003e\r\nImportant clinical considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eVolume Overload\u003c\/li\u003e\r\n \t\u003cli\u003eCongestion\u003c\/li\u003e\r\n \t\u003cli\u003eDiuretic Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eRenal Dysfunction\u003c\/li\u003e\r\n \t\u003cli\u003eInpatient Management\u003c\/li\u003e\r\n \t\u003cli\u003eDecongestion Strategies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eHospital Discharge Planning\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCardiogenic Shock\u003c\/h3\u003e\r\nCardiogenic shock is a major cause of morbidity and mortality among patients with severe cardiac dysfunction.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCardiogenic Shock Recognition\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Profiles\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eVasoactive Medications\u003c\/li\u003e\r\n \t\u003cli\u003eInvasive Hemodynamic Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eTemporary Mechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary Shock Teams\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Escalation\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe scientific program addresses contemporary approaches to advanced acute heart failure care.\r\n\u003ch2\u003eSession III – Mechanical Circulatory Support\u003c\/h2\u003e\r\n\u003ch3\u003eTemporary Mechanical Circulatory Support\u003c\/h3\u003e\r\nTemporary mechanical support may be considered in selected patients with severe hemodynamic compromise.\r\n\r\nImportant concepts include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIntra-Aortic Balloon Pump\u003c\/li\u003e\r\n \t\u003cli\u003ePercutaneous Ventricular Assist Devices\u003c\/li\u003e\r\n \t\u003cli\u003eVA-ECMO\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Support\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Selection\u003c\/li\u003e\r\n \t\u003cli\u003eVascular Complications\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Escalation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eDurable Left Ventricular Assist Devices\u003c\/h3\u003e\r\nDurable mechanical circulatory support is relevant to patients with advanced heart failure.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eLVAD Candidate Selection\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Heart Failure Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eSurgical Implantation\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation\u003c\/li\u003e\r\n \t\u003cli\u003eRight Ventricular Failure\u003c\/li\u003e\r\n \t\u003cli\u003eDevice-Related Infection\u003c\/li\u003e\r\n \t\u003cli\u003ePump Thrombosis\u003c\/li\u003e\r\n \t\u003cli\u003eGastrointestinal Bleeding\u003c\/li\u003e\r\n \t\u003cli\u003eQuality of Life\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program includes scientific research relevant to device treatment and patient outcomes.\r\n\u003ch2\u003eSession IV – Heart Transplantation\u003c\/h2\u003e\r\n\u003ch3\u003eAdvanced Heart Failure and Transplant Cardiology\u003c\/h3\u003e\r\nHeart transplantation remains an important treatment option for selected patients with advanced heart failure.\r\n\r\nRelevant educational areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTransplant Candidate Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Transplant Listing\u003c\/li\u003e\r\n \t\u003cli\u003eRecipient Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eDonor Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eOrgan Allocation\u003c\/li\u003e\r\n \t\u003cli\u003eImmunosuppression\u003c\/li\u003e\r\n \t\u003cli\u003eGraft Rejection\u003c\/li\u003e\r\n \t\u003cli\u003eInfection Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Allograft Vasculopathy\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Transplant Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTreatment Sequencing in Advanced Heart Failure\u003c\/h3\u003e\r\nThe 2026 meeting includes research relevant to treatment sequencing, particularly the relationship between mechanical support and heart transplantation.\r\n\r\nClinical considerations include patient selection, expected outcomes, risk assessment, and timing of intervention.\r\n\u003ch2\u003eSession V – Cardiomyopathies and Infiltrative Heart Disease\u003c\/h2\u003e\r\n\u003ch3\u003eCardiac Amyloidosis\u003c\/h3\u003e\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTransthyretin Amyloid Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eAL Amyloidosis\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eBiomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eDisease-Specific Treatment\u003c\/li\u003e\r\n \t\u003cli\u003ePrognosis\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHypertrophic Cardiomyopathy\u003c\/h3\u003e\r\nRelevant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eObstructive HCM\u003c\/li\u003e\r\n \t\u003cli\u003eNonobstructive HCM\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Imaging\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Capacity\u003c\/li\u003e\r\n \t\u003cli\u003eSudden Cardiac Death Risk\u003c\/li\u003e\r\n \t\u003cli\u003eMyosin Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Clinical Trials\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAdditional Cardiomyopathies\u003c\/h3\u003e\r\nOther clinically important topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCardiac Sarcoidosis\u003c\/li\u003e\r\n \t\u003cli\u003eMyocarditis\u003c\/li\u003e\r\n \t\u003cli\u003eInherited Cardiomyopathies\u003c\/li\u003e\r\n \t\u003cli\u003eDilated Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eArrhythmogenic Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic Counseling\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Imaging\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational emphasis is on recognizing disease-specific mechanisms and selecting appropriate investigations and treatment approaches.\r\n\u003ch2\u003eSession VI – Cardiorenal-Metabolic Medicine\u003c\/h2\u003e\r\n\u003ch3\u003eHeart Failure and Kidney Disease\u003c\/h3\u003e\r\nCardiorenal interactions create important treatment challenges.\r\n\r\nRelevant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCardiorenal Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Kidney Disease\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Kidney Injury\u003c\/li\u003e\r\n \t\u003cli\u003eVolume Management\u003c\/li\u003e\r\n \t\u003cli\u003eDiuretic Response\u003c\/li\u003e\r\n \t\u003cli\u003eRenal Function Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eObesity, Diabetes and Heart Failure\u003c\/h3\u003e\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eType 2 Diabetes\u003c\/li\u003e\r\n \t\u003cli\u003eObesity\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Dysfunction\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eWeight Management\u003c\/li\u003e\r\n \t\u003cli\u003eCardiometabolic Risk\u003c\/li\u003e\r\n \t\u003cli\u003eHFpEF\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program emphasizes the growing importance of integrating metabolic and renal disease management into cardiovascular care.\r\n\u003ch2\u003eSession VII – Electrophysiology and Cardiac Devices\u003c\/h2\u003e\r\n\u003ch3\u003eCardiac Resynchronization Therapy\u003c\/h3\u003e\r\nRelevant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCRT\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eVentricular Dyssynchrony\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Programming\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Response\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eImplantable Cardioverter-Defibrillators\u003c\/h3\u003e\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSudden Cardiac Death Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eICD Indications\u003c\/li\u003e\r\n \t\u003cli\u003eVentricular Arrhythmias\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Selection\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eDevice Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eConduction System Pacing and Catheter Ablation\u003c\/h3\u003e\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHis-Bundle Pacing\u003c\/li\u003e\r\n \t\u003cli\u003eLeft Bundle Branch Area Pacing\u003c\/li\u003e\r\n \t\u003cli\u003ePhysiological Pacing\u003c\/li\u003e\r\n \t\u003cli\u003eAtrial Fibrillation\u003c\/li\u003e\r\n \t\u003cli\u003eCatheter Ablation\u003c\/li\u003e\r\n \t\u003cli\u003eRhythm Control\u003c\/li\u003e\r\n \t\u003cli\u003eVentricular Function\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese subjects reflect the relationship between electrophysiology and heart failure management.\r\n\u003ch2\u003eSession VIII – Digital Health, Remote Monitoring and Artificial Intelligence\u003c\/h2\u003e\r\n\u003ch3\u003eRemote Patient Monitoring\u003c\/h3\u003e\r\nImportant educational areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eRemote Hemodynamic Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003ePulmonary Artery Pressure Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eCongestion Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eDigital Health\u003c\/li\u003e\r\n \t\u003cli\u003eRemote Clinical Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eEarly Detection of Deterioration\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Hospitalization Prevention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eArtificial Intelligence in Heart Failure\u003c\/h3\u003e\r\nEmerging research explores the use of artificial intelligence for:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eRisk Prediction\u003c\/li\u003e\r\n \t\u003cli\u003eImaging Analysis\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Decision Support\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eDigital Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Workflows\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese approaches require attention to clinical validation, reliability, bias, patient privacy, and clinician oversight.\r\n\u003ch2\u003eSession IX – Health Equity and Multidisciplinary Care\u003c\/h2\u003e\r\nHeart failure management is influenced by medical, social, economic, and healthcare delivery factors.\r\n\r\nImportant themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHealth Equity\u003c\/li\u003e\r\n \t\u003cli\u003eAccess to Care\u003c\/li\u003e\r\n \t\u003cli\u003eSocial Determinants of Health\u003c\/li\u003e\r\n \t\u003cli\u003eMedication Access\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary Teams\u003c\/li\u003e\r\n \t\u003cli\u003eNursing Care\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacist-Led Optimization\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Education\u003c\/li\u003e\r\n \t\u003cli\u003eShared Decision-Making\u003c\/li\u003e\r\n \t\u003cli\u003ePalliative Care\u003c\/li\u003e\r\n \t\u003cli\u003eQuality of Life\u003c\/li\u003e\r\n \t\u003cli\u003eCare Transitions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program emphasizes comprehensive and patient-centered management.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eOfficial Late-Breaking Clinical Research 2026\u003c\/h1\u003e\r\nThe following are examples of research included in the official HFSA 2026 scientific program. These are not a verified inventory of recordings supplied by MedicalAmboss.\r\n\u003ch2\u003eREBALANCE Registry\u003c\/h2\u003e\r\n\u003ch3\u003eReal-World Outcomes Following Baroreflex Activation Therapy\u003c\/h3\u003e\r\nThe REBALANCE Registry examines outcomes related to baroreflex activation therapy in patients with heart failure.\r\n\r\nRelevant research areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBaroreflex Activation Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Symptoms\u003c\/li\u003e\r\n \t\u003cli\u003eDevice-Based Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eReal-World Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eACACIA-HCM\u003c\/h2\u003e\r\n\u003ch3\u003eGlobal Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy\u003c\/h3\u003e\r\nThe ACACIA-HCM trial examines aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy.\r\n\r\nRelevant scientific themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNonobstructive HCM\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Myosin Inhibition\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Performance\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Symptoms\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Trial Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe official program also includes a prespecified analysis of exercise performance.\r\n\u003ch2\u003ePOSEIDON Study\u003c\/h2\u003e\r\n\u003ch3\u003eCardiovascular Inflammation Across the Heart Failure Spectrum\u003c\/h3\u003e\r\nThe POSEIDON research examines cardiovascular inflammation and associated biomarker profiles in patients with different heart failure phenotypes.\r\n\r\nImportant concepts include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eInflammation\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Phenotypes\u003c\/li\u003e\r\n \t\u003cli\u003eBiomarker Profiles\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Risk\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Characterization\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eC-MIC II and C-MIC III\u003c\/h2\u003e\r\n\u003ch3\u003eCardiac Microcurrent Therapy and Exercise Capacity\u003c\/h3\u003e\r\nThese studies examine cardiac microcurrent therapy in relation to exercise capacity and patient outcomes.\r\n\r\nRelevant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eDevice-Based Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eCardiopulmonary Exercise Testing\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Capacity\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Trial Analysis\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eATTRibute-CM Research\u003c\/h2\u003e\r\n\u003ch3\u003eSerum Transthyretin and NT-proBNP as Prognostic Measures\u003c\/h3\u003e\r\nThis research evaluates the relationship between transthyretin and NT-proBNP measurements in patients with transthyretin amyloid cardiomyopathy.\r\n\r\nRelevant concepts include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eATTR Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eNT-proBNP\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eHF-TRACK Trial\u003c\/h2\u003e\r\n\u003ch3\u003eAmbient Home Monitoring of Peripheral Edema\u003c\/h3\u003e\r\nThe HF-TRACK trial evaluates remote monitoring of peripheral edema and its relationship to heart failure events.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eRemote Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003ePeripheral Edema\u003c\/li\u003e\r\n \t\u003cli\u003eCongestion Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Events\u003c\/li\u003e\r\n \t\u003cli\u003eDigital Health\u003c\/li\u003e\r\n \t\u003cli\u003eHome Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eAcoramidis and Tafamidis Research\u003c\/h2\u003e\r\nThe scientific program includes studies comparing or evaluating treatments for transthyretin amyloid cardiomyopathy.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eATTR-CM\u003c\/li\u003e\r\n \t\u003cli\u003eAcoramidis\u003c\/li\u003e\r\n \t\u003cli\u003eTafamidis\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Effectiveness\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Outcomes\u003c\/li\u003e\r\n \t\u003cli\u003eReal-World Evidence\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMajor Topics Covered\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHFSA Annual Scientific Meeting 2026\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Society of America\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eHFrEF\u003c\/li\u003e\r\n \t\u003cli\u003eHFmrEF\u003c\/li\u003e\r\n \t\u003cli\u003eHFpEF\u003c\/li\u003e\r\n \t\u003cli\u003eGuideline-Directed Medical Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Decompensated Heart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eCardiogenic Shock\u003c\/li\u003e\r\n \t\u003cli\u003eHemodynamic Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eTemporary Mechanical Circulatory Support\u003c\/li\u003e\r\n \t\u003cli\u003eLVAD\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Amyloidosis\u003c\/li\u003e\r\n \t\u003cli\u003eHypertrophic Cardiomyopathy\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Sarcoidosis\u003c\/li\u003e\r\n \t\u003cli\u003eMyocarditis\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic Cardiomyopathies\u003c\/li\u003e\r\n \t\u003cli\u003eCardiorenal Syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Heart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eSGLT2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eMineralocorticoid Receptor Antagonists\u003c\/li\u003e\r\n \t\u003cli\u003eCardiac Resynchronization Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eICD\u003c\/li\u003e\r\n \t\u003cli\u003eConduction System Pacing\u003c\/li\u003e\r\n \t\u003cli\u003eCatheter Ablation\u003c\/li\u003e\r\n \t\u003cli\u003eRemote Patient Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eArtificial Intelligence in Cardiology\u003c\/li\u003e\r\n \t\u003cli\u003eHeart Failure Prevention\u003c\/li\u003e\r\n \t\u003cli\u003eHealth Equity\u003c\/li\u003e\r\n \t\u003cli\u003ePalliative Care\u003c\/li\u003e\r\n \t\u003cli\u003eLate-Breaking Clinical Trials\u003c\/li\u003e\r\n \t\u003cli\u003eCardiovascular Research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eAdvanced Heart Failure and Cardiovascular Outcomes\u003c\/h2\u003e\r\nThe HFSA 2026 scientific program emphasizes treatment approaches relevant to patients with advanced and refractory heart failure.\r\n\r\nThese include pharmacotherapy, mechanical support, heart transplantation, device-based treatment, and coordinated multidisciplinary care.\r\n\u003ch2\u003ePrecision Medicine in Cardiomyopathy\u003c\/h2\u003e\r\nAdvances in genetic evaluation, imaging, biomarkers, and disease-specific therapies are influencing the diagnosis and management of cardiomyopathies.\r\n\r\nThe conference includes research relevant to cardiac amyloidosis, hypertrophic cardiomyopathy, and other important myocardial disorders.\r\n\u003ch2\u003eEmerging Pharmacology and Clinical Trials\u003c\/h2\u003e\r\nThe 2026 meeting includes scientific research evaluating established and emerging heart failure treatments.\r\n\r\nThe program provides an opportunity to assess clinical trial design, treatment outcomes, patient selection, and potential implications for practice.\r\n\u003ch2\u003ePatient-Centered Heart Failure Care\u003c\/h2\u003e\r\nHeart failure management extends beyond medication and device therapy.\r\n\r\nThe program addresses multidisciplinary care, health equity, quality improvement, remote monitoring, palliative care, and long-term patient outcomes.\r\n\u003ch2\u003eProgram Leadership\u003c\/h2\u003e\r\n\u003ch3\u003eJennifer Thibodeau, MD, MSCS, FHFSA, FACC, FAHA\u003c\/h3\u003e\r\n\u003cstrong\u003e2026 HFSA Annual Scientific Meeting Program Committee Chair\u003c\/strong\u003e\r\n\r\nThe scientific meeting brings together researchers and clinicians from multiple cardiovascular specialties, with contributions from multidisciplinary heart failure teams.\r\n\u003ch2\u003eContinuing Medical Education\u003c\/h2\u003e\r\nThe original HFSA Annual Scientific Meeting 2026 offered accredited continuing education opportunities for eligible participants.\r\n\r\nAvailable credit types and amounts depended on the specific activity, professional category, and participation requirements.\r\n\r\nOriginal registered attendees could access eligible on-demand sessions through \u003cstrong\u003eJanuary 7, 2027\u003c\/strong\u003e.\r\n\u003ch3\u003eImportant CME Notice\u003c\/h3\u003e\r\nPurchasing separately distributed educational files through MedicalAmboss does not itself provide:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eOfficial HFSA CME Credits\u003c\/li\u003e\r\n \t\u003cli\u003eABIM MOC Points\u003c\/li\u003e\r\n \t\u003cli\u003eNursing Continuing Education Credits\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacy Continuing Education Credits\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Completion Certificates\u003c\/li\u003e\r\n \t\u003cli\u003eHFSA Membership\u003c\/li\u003e\r\n \t\u003cli\u003eOriginal Conference Registration\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher On-Demand Platform Access\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial HFSA Accounts\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher-Hosted Educational Extras\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eWhy This Course Is Relevant\u003c\/h2\u003e\r\nThe \u003cstrong\u003eHeart Failure Society of America Annual Scientific Meeting 2026\u003c\/strong\u003e provides a broad educational overview of contemporary heart failure science and clinical practice.\r\n\r\nIts scientific scope encompasses pharmacotherapy, cardiogenic shock, mechanical support, transplantation, cardiomyopathies, cardiorenal-metabolic medicine, electrophysiology, digital health, and multidisciplinary care.\r\n\r\nThe conference is especially relevant to heart failure specialists, general cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons, nephrologists, and other healthcare professionals involved in heart failure management.\r\n\r\nThe integration of late-breaking scientific research and practical clinical education supports understanding of new developments affecting the treatment of patients with heart failure.\r\n\u003ch2\u003eOfficial Program Reference and MedicalAmboss Purchase Scope\u003c\/h2\u003e\r\n\u003cstrong\u003eOfficial HFSA Annual Scientific Meeting 2026:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/hfsa.org\/asm\/hfsa-annual-scientific-meeting-2026\" data-rich-text-autolink=\"\"\u003ehttps:\/\/hfsa.org\/asm\/hfsa-annual-scientific-meeting-2026\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial 2026 Scientific Schedule:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/hfsa.org\/asm\/schedule-glance\" data-rich-text-autolink=\"\"\u003ehttps:\/\/hfsa.org\/asm\/schedule-glance\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial 2026 Late-Breaking Clinical Research:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/hfsa.org\/asm\/late-breaking-clinical-research-2026\" data-rich-text-autolink=\"\"\u003ehttps:\/\/hfsa.org\/asm\/late-breaking-clinical-research-2026\u003c\/a\u003e\r\n\r\nThese official references describe the original conference, its educational program, scientific research, venue, dates, and attendee access.\r\n\r\nThey do not independently establish the exact inventory of files included in any separately distributed MedicalAmboss product.\r\n\r\n\u003cstrong\u003eMedicalAmboss File Scope:\u003c\/strong\u003e This listing describes the educational subject matter for reference. Original conference registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eShort Description\u003c\/h2\u003e\r\n\u003cstrong\u003eHeart Failure Society of America Annual Scientific Meeting 2026\u003c\/strong\u003e provides an extensive scientific and clinical update in heart failure medicine, advanced cardiovascular care, emerging treatments, mechanical circulatory support, cardiomyopathies, and transplantation.\r\n\r\nHeld \u003cstrong\u003eOctober 9–12, 2026, in Phoenix, Arizona\u003c\/strong\u003e, the original HFSA meeting includes expert scientific presentations, case-based education, multidisciplinary discussions, and late-breaking clinical research.\r\n\u003ch2\u003eTopics\u003c\/h2\u003e\r\n\u003ch3\u003eTrack 1: Chronic Heart Failure \u0026amp; Guideline-Directed Medical Therapy (GDMT)\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eRapid Sequencing and Optimization of the Four Pillars of HFrEF Therapy (ARNI, Beta-Blockers, MRA, SGLT2i)\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Algorithms and Phenotype-Specific Management of HFpEF and HFmrEF\u003c\/li\u003e\r\n \t\u003cli\u003eManagement of Heart Failure with Improved Ejection Fraction (HFimpEF)\u003c\/li\u003e\r\n \t\u003cli\u003eOvercoming Therapeutic Inertia: Strategies for Titrating GDMT in Outpatient and Inpatient Settings\u003c\/li\u003e\r\n \t\u003cli\u003eNovel Pharmacotherapies in Clinical Trials: Soluble Guanylate Cyclase Stimulators, Cardiac Myosin Activators\/Inhibitors, and Anti-Inflammatory Agents\u003c\/li\u003e\r\n \t\u003cli\u003eManaging Worsening Heart Failure (WHF) Events in the Ambulatory Setting\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 2: Acute Heart Failure, Cardiogenic Shock \u0026amp; Critical Care Cardiology\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eContemporary Classification and Staging of Cardiogenic Shock (SCAI Shock Stages)\u003c\/li\u003e\r\n \t\u003cli\u003eInvasive Hemodynamic Assessment and Pulmonary Artery Catheterization in the Cardiac Intensive Care Unit (CICU)\u003c\/li\u003e\r\n \t\u003cli\u003eDecongestion Strategies in Acute Decompensated Heart Failure: Diuretic Resistance, Sequential Nephron Blockade, and Ultrafiltration\u003c\/li\u003e\r\n \t\u003cli\u003eTemporary Mechanical Circulatory Support (tMCS): Intra-Aortic Balloon Pump (IABP), Impella, TandemHeart, and VA-ECMO\u003c\/li\u003e\r\n \t\u003cli\u003eShock Team Protocols, Regionalized Networks, and Escalation\/De-escalation Algorithms\u003c\/li\u003e\r\n \t\u003cli\u003eManagement of Right Ventricular Failure in the Critically Ill Patient\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 3: Advanced Heart Failure, Durable MCS \u0026amp; Heart Transplantation\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePatient Selection and Timing of Referral for Advanced Heart Failure Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eDurable Left Ventricular Assist Devices (LVAD): Hemocompatibility, Pump Thrombosis, GI Bleeding, and Driveline Infections\u003c\/li\u003e\r\n \t\u003cli\u003eAdvances in Heart Transplantation: Donor Pool Expansion, Donation After Circulatory Death (DCD), and Ex Vivo Organ Perfusion\u003c\/li\u003e\r\n \t\u003cli\u003eContemporary Immunosuppression Regimens and Desensitization Strategies in Sensitized Transplant Candidates\u003c\/li\u003e\r\n \t\u003cli\u003eNon-Invasive Surveillance for Cardiac Allograft Rejection: Donor-Derived Cell-Free DNA (dd-cfDNA) and Gene Expression Profiling\u003c\/li\u003e\r\n \t\u003cli\u003ePrevention, Diagnosis, and Management of Cardiac Allograft Vasculopathy (CAV)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 4: Cardiomyopathies, Myocarditis \u0026amp; Genetic Heart Disease\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTransthyretin Cardiac Amyloidosis (ATTR-CM): Non-Invasive Diagnosis, TTR Stabilizers, Silencers, and Emerging Depleters\u003c\/li\u003e\r\n \t\u003cli\u003eHypertrophic Cardiomyopathy (HCM): Integration of Cardiac Myosin Inhibitors, Septal Reduction Therapy, and Sudden Death Risk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eInflammatory Cardiomyopathies: Diagnostic Imaging and Immunosuppression in Cardiac Sarcoidosis and Giant Cell Myocarditis\u003c\/li\u003e\r\n \t\u003cli\u003eAcute and Fulminant Myocarditis: Etiologies, Endomyocardial Biopsy Indications, and Long-Term Sequelae\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic Testing and Cascade Screening in Dilated, Arrhythmogenic, and Non-Compaction Cardiomyopathies\u003c\/li\u003e\r\n \t\u003cli\u003ePeripartum Cardiomyopathy and Cardio-Obstetrics: Risk Stratification and Management Across Pregnancy\u003c\/li\u003e\r\n \t\u003cli\u003eCardio-Oncology: Prevention, Surveillance, and Management of Cancer Therapy-Related Cardiac Dysfunction (CTRCD)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 5: Cardiorenal-Metabolic Syndrome \u0026amp; Comorbidities\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eThe Cardiorenal-Metabolic Axis: Interplay Between Heart Failure, Chronic Kidney Disease (CKD), Diabetes, and Obesity\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists and Dual GIP\/GLP-1 Agonists in Obesity-Related HFpEF\u003c\/li\u003e\r\n \t\u003cli\u003eManaging Hyperkalemia and Worsening Renal Function During RAASi and MRA Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnosis and Treatment of Iron Deficiency and Anemia in Heart Failure: Intravenous Iron Supplementation\u003c\/li\u003e\r\n \t\u003cli\u003eSleep-Disordered Breathing (Obstructive and Central Sleep Apnea) in Heart Failure\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 6: Pulmonary Hypertension \u0026amp; Right Heart Failure\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDifferentiating Pulmonary Arterial Hypertension (PAH – Group 1) from Pulmonary Hypertension Due to Left Heart Disease (PH-LHD – Group 2)\u003c\/li\u003e\r\n \t\u003cli\u003eInvasive Hemodynamic Exercise Testing in Unexplained Dyspnea and Combined Pre- and Post-Capillary PH (CpcPH)\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted Pulmonary Vasodilator Therapies and Emerging Activin Signaling Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eComprehensive Evaluation and Management of Isolated Right Ventricular Failure and Tricuspid Regurgitation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 7: Electrophysiology, Devices \u0026amp; Structural Heart Interventions in Heart Failure\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAtrial Fibrillation in Heart Failure: Catheter Ablation vs. Medical Therapy and Rate\/Rhythm Control\u003c\/li\u003e\r\n \t\u003cli\u003eVentricular Arrhythmias in Ischemic and Non-Ischemic Cardiomyopathy: ICD Indications and Catheter Ablation\u003c\/li\u003e\r\n \t\u003cli\u003eAdvances in Pacing: Cardiac Resynchronization Therapy (CRT), His-Bundle Pacing, and Left Bundle Branch Area Pacing (LBBAP)\u003c\/li\u003e\r\n \t\u003cli\u003eNeuromodulation and Device-Based Therapies: Cardiac Contractility Modulation (CCM) and Baroreflex Activation Therapy (BAT)\u003c\/li\u003e\r\n \t\u003cli\u003eTranscatheter Edge-to-Edge Repair (TEER) and Transcatheter Valve Replacement for Secondary Mitral and Tricuspid Regurgitation\u003c\/li\u003e\r\n \t\u003cli\u003eImplantable Hemodynamic Monitors and Remote Dielectric Sensing for Guiding Heart Failure Therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eTrack 8: Multidisciplinary Care, Digital Health, Health Equity \u0026amp; Palliative Care\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eArtificial Intelligence, Machine Learning, and Wearable Technologies in Heart Failure Prediction and Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eOptimizing Transitions of Care, Post-Discharge Clinics, and Hospital-at-Home Models\u003c\/li\u003e\r\n \t\u003cli\u003eAddressing Social Determinants of Health (SDOH) and Disparities in Heart Failure Outcomes and Transplant Allocation\u003c\/li\u003e\r\n \t\u003cli\u003eExercise Training, Cardiac Rehabilitation, and Nutritional Interventions in Heart Failure\u003c\/li\u003e\r\n \t\u003cli\u003eShared Decision-Making, Advance Care Planning, Symptom Management, and Palliative Care in End-Stage Heart Failure\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"medicalamboss-related-resources\"\u003e\u003c\/div\u003e\r\n\u003c!-- MAA:RELATED:END --\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":67982425129114,"sku":"MED-AMB10540","price":180.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/macs-0efe51bcb5-50442-51068-0fca431061071e07beb4.jpg?v=1793145987","url":"https:\/\/ambosscourse.com\/products\/wc-0efe51bcb5f34c14-50442","provider":"Amboss","version":"1.0","type":"link"}